{"ticker": {"uuid": "a6219535-ea2f-4fc5-861f-203d4a62ab55", "symbol": "JAZZ", "name": "Jazz Pharmaceuticals PLC", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Jazz Pharmaceuticals stock hits all-time high at 250.85 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNOVU2TzNESXpsc01pZWw0NUlHVVUteXVQZmZiMnUwZ3h3QTlmR1BMZVFlcEo5aVdTTzBDZ1A1ZU1wNzBENXpBSEU4dEZHd2E5TXMtLWRPNGF6N3pzbmdlYTlOWm9sZEcybVptZS1ranV3c1pZMjRoVDl1ZTFmTE1BcnhBcXZUQTJKdk5EUXB4bFBRd1V0eEt6UUhpdXlCYzlUdHl5MWNqZTEyenZZSGgxVVptYy0?oc=5", "source_name": "Investing.com", "published_at": "2026-07-21T16:38:54+00:00", "published_display": "21 Jul 2026 16:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals sets Aug. 3 webcast after market close", "summary": "Jazz Pharmaceuticals (Nasdaq: JAZZ) announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close of U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to review results and provide a business and financi", "url": "https://www.stocktitan.net/news/JAZZ/jazz-pharmaceuticals-to-report-second-quarter-financial-results-on-7yj4racuhw9r.html", "source_name": "Stock Titan", "published_at": "2026-07-20T20:18:23", "published_display": "20 Jul 2026 20:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026", "summary": "Jazz Pharmaceuticals plc announced it will report its second-quarter 2026 financial results on Monday, August 3, 2026, after the close of U.S. financial markets. The company's management will host a webcast at 4:30 p.m. ET to discuss the results and provide business and financial", "url": "https://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-to-report-second-quarter-financial-results-on-august-3-2026-302829880.html", "source_name": "PR Newswire UK", "published_at": "2026-07-20T20:15:23", "published_display": "20 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Jazz\u2019s Sleep and Oncology Pipeline Momentum Just Shift Jazz Pharmaceuticals' (JAZZ) Investment Narrative?", "summary": "Jazz Pharmaceuticals is gaining investor attention due to its sleep-disorder and oncology portfolios, particularly with progress in its pipeline and franchise positioning. The company's investment narrative depends on its ability to leverage these franchises to offset patent clif", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/did-jazzs-sleep-and-oncology-pipeline-momentum-just-shift-ja/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-19T19:40:32", "published_display": "19 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Q1 2026 earnings summary", "summary": "Jazz Pharmaceuticals (JAZZ) reported record Q1 2026 revenues of $1.1 billion, a 19% year-over-year increase, driven by strong growth in its sleep, epilepsy, and oncology portfolios. The company achieved a net income of $293.1 million, a significant improvement from a Q1 2025 net ", "url": "https://quartr.com/events/jazz-pharmaceuticals-jazz-q1-2026_oC4svVf7", "source_name": "Quartr", "published_at": "2026-07-19T02:11:12", "published_display": "19 Jul 2026 02:11", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Stock Still Looks Like A Bargain After A 119% Run", "summary": "Jazz Pharmaceuticals (JAZZ) has seen a significant 119.3% return over the past year, prompting an evaluation of its current valuation. Despite this strong performance, Simply Wall St's analysis suggests the stock appears undervalued on several measures, trading at a P/S ratio (3.", "url": "https://uk.finance.yahoo.com/news/jazz-pharmaceuticals-jazz-stock-still-111411652.html", "source_name": "Market source", "published_at": "2026-07-18T11:09:29", "published_display": "18 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Refocuses Its Sleep Franchise, Is The Stock Still Cheap?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPbGNyTjRDemN6U21hcXVmaXc1Qk81YmhvSENud09RbHRoWURIVk1kTWI3dlBSNW1SUlhHUmttZmRGcllucElnMTVqZ091ZEJiS3dicW4wdVFnekVxWG9MSUdrZ3Q4WkQ0azBjSHBkMl93Q0VsdnB1eHI5aUh0T1Q5UzVTbTVsUEpLVmtaTlhONE9DdldGVU5oU0Y0RV9wR1pnQkxzVQ?oc=5", "source_name": "Market source", "published_at": "2026-07-18T07:11:42+00:00", "published_display": "18 Jul 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Upgrades Jazz Pharmaceuticals(JAZZ.US) to Buy Rating, Announces Target Price $290", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQNWs1MkVrRUdLZ25EckhQaGdZaVNTSDBxb3QtZEVMWERSNFQ4aEpLZkkycGY3TFNBcTZqeHRWb1VNQ2pPakZJTkNuVE52dG9VVEFGbW5jVGtvQThScDNjR09pcmRPMmZBVUJIVWFYSlAwc0NaTUlRejZ6V2psd2lNdXFQbnQwbUJRWHhNRGxQVVFyNG9NNE55NFV5TTN1UDQ1dVZjTW8xbEhlSEltNEpWejNjTEs1dw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-17T16:40:04+00:00", "published_display": "17 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord Genuity Initiates Coverage on Jazz Pharmaceuticals With Buy Rating, $290 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/canaccord-genuity-initiates-coverage-jazz-112031961.html", "source_name": "MT Newswires", "published_at": "2026-07-17T11:20:31+00:00", "published_display": "17 Jul 2026 11:20", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JAZZ PHARMACEUTICALS PLC : CANACCORD GENUITY INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $290", "summary": "Canaccord Genuity has initiated coverage on Jazz Pharmaceuticals PLC (JAZZ.O) with a \"BUY\" rating. The firm has set a target price of $290 for the company's shares. This report originated from Reuters and was published on July 17, 2026, at 04:40.", "url": "https://www.bitget.com/asia/news/detail/12560605512956", "source_name": "Bitget", "published_at": "2026-07-16T20:39:53", "published_display": "16 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 94, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Jazz Pharmaceuticals (JAZZ) Still Undervalued On Its Oncology And Neuroscience Growth Story?", "summary": "Jazz Pharmaceuticals (JAZZ) has shown strong share price performance and revenue growth, leading to a narrative that pegs it as 7.4% undervalued with a fair value of $257.00. This optimism stems from the expected approval and launch of new therapies, particularly within its oncol", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/is-jazz-pharmaceuticals-jazz-still-undervalued-on-its-oncolo/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-15T00:45:30", "published_display": "15 Jul 2026 00:45", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Jazz Pharmaceuticals (JAZZ) Q4 2025 earnings summary", "summary": "Jazz Pharmaceuticals reported record total revenue of $4.3 billion in 2025, a 5% increase year-over-year, with Q4 revenue reaching $1.2 billion, up 10%. Three of its franchises\u2014rare sleep, rare epilepsy, and rare oncology\u2014each surpassed $1 billion in annual revenue. The company a", "url": "https://quartr.com/events/jazz-pharmaceuticals-plc-jazz-q4-2025_oC4sJU67", "source_name": "Quartr", "published_at": "2026-07-12T20:40:32", "published_display": "12 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Q1 2025 earnings summary", "summary": "Jazz Pharmaceuticals (JAZZ) reported Q1 2025 revenues between $897.8M and $902M, driven by strong growth in Xywav and Epidiolex, despite declines in oncology and Xyrem. The company affirmed its 2025 revenue guidance of $4.15\u2013$4.4 billion and expects Epidiolex to achieve blockbust", "url": "https://quartr.com/events/jazz-pharmaceuticals-plc-jazz-q1-2025_oC4sJPF0", "source_name": "Quartr", "published_at": "2026-07-10T07:13:02", "published_display": "10 Jul 2026 07:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JAZZ Maintained by Deutsche Bank -- Price Target Raised to $270", "summary": "Deutsche Bank has maintained a 'Buy' rating on Jazz Pharmaceuticals (JAZZ) and raised its price target from $250 to $270, indicating an 8% projected increase. Despite this positive analyst outlook, GuruFocus data suggests JAZZ is significantly overvalued by 63.5% based on its GF ", "url": "https://www.gurufocus.com/news/8952212/jazz-maintained-by-deutsche-bank-price-target-raised-to-270", "source_name": "GuruFocus", "published_at": "2026-07-09T21:10:50", "published_display": "09 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Status Update Summary", "summary": "Jazz Pharmaceuticals' (JAZZ) Phase III IMforte trial demonstrated significant improvement in progression-free survival and overall survival for extensive-stage small cell lung cancer patients treated with lurbinectedin plus atezolizumab. This regimen is now positioned as a potent", "url": "https://quartr.com/events/jazz-pharmaceuticals-plc-jazz-status-update_oC4sJANL", "source_name": "Quartr", "published_at": "2026-07-09T06:10:25", "published_display": "09 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Q4 2024 earnings summary", "summary": "Jazz Pharmaceuticals achieved record total revenues of $4.1 billion in 2024, a 6% year-over-year increase, with Q4 revenue reaching nearly $1.1 billion. Key growth drivers included Xywav and Epidiolex, and the company made significant progress in its R&D pipeline with FDA approva", "url": "https://quartr.com/events/jazz-pharmaceuticals-plc-jazz-q4-2024_oC4sldIq", "source_name": "Quartr", "published_at": "2026-07-09T05:41:26", "published_display": "09 Jul 2026 05:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Q3 2024 earnings summary", "summary": "Jazz Pharmaceuticals reported record Q3 2024 revenues of $1.05 billion, a 9% year-over-year increase, driven by strong sales of Xywav, Epidiolex, and Zepzelca. Net income rose significantly to $215.1 million, with adjusted EPS increasing by 37% to $6.61. The company affirmed its ", "url": "https://quartr.com/events/jazz-pharmaceuticals-plc-jazz-q3-2024_oC4slb3e", "source_name": "Quartr", "published_at": "2026-07-09T05:41:26", "published_display": "09 Jul 2026 05:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Jefferies Global Healthcare Conference Summary", "summary": "Jazz Pharmaceuticals shared an event summary from the Jefferies Global Healthcare Conference on July 8, 2026, highlighting significant progress in commercial activities, R&D, and corporate development, including the integration of Zymeworks and zanidatamab. The company provided a", "url": "https://quartr.com/events/jazz-pharmaceuticals-plc-jazz-jefferies-global-healthcare-conference_oC4sv3Rx", "source_name": "Quartr", "published_at": "2026-07-09T05:10:50", "published_display": "09 Jul 2026 05:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks", "summary": "This article lists various ETFs that hold stocks of Jazz Pharmaceuticals Public Limited Company (JAZZ/N), providing details like market value, weight, issuer, management style, focus, expense ratio, AUM, price, and 3-year NAV total return for each fund. The ETFs listed range acro", "url": "https://www.tradingview.com/symbols/BIVA-JAZZ/N/etfs/", "source_name": "TradingView", "published_at": "2026-07-08T12:10:30", "published_display": "08 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) director Cozadd sells 6,000 shares via 10b5-1 trade", "summary": "Jazz Pharmaceuticals plc director Bruce C. Cozadd reported an open-market sale of 6,000 Ordinary Shares of JAZZ on July 1, 2026, at an average price of $240.47 per share, totaling $1.44 million. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted ", "url": "https://www.stocktitan.net/sec-filings/JAZZ/form-4-jazz-pharmaceuticals-plc-insider-trading-activity-ce06590bf5ed.html", "source_name": "Stock Titan", "published_at": "2026-07-07T17:39:59", "published_display": "07 Jul 2026 17:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JAZZ - Jazz Pharmaceuticals plc Options", "summary": "This article provides a detailed financial overview of Jazz Pharmaceuticals plc (JAZZ), including its last closing price, market capitalization, key financial ratios, EPS and sales growth rates, and various performance metrics. It also lists insider and institutional ownership, p", "url": "https://finviz.com/stock?t=JAZZ&ta=1&p=m&ty=oc&r=max&ov=list_strike&s=250", "source_name": "Finviz", "published_at": "2026-07-03T15:10:41", "published_display": "03 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Breakout Keeps Valuation In Focus Following Zepzelca Setback And Ziihera Hopes", "summary": "Jazz Pharmaceuticals (JAZZ) stock has broken out of a long-term trading base near an all-time high, driven by mixed news regarding its cancer drug Zepzelca and optimism surrounding Ziihera. Despite a 122.45% 1-year return, the company is considered 5.3% undervalued, with a fair v", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/jazz-pharmaceuticals-jazz-breakout-keeps-valuation-in-focus/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-03T02:09:18", "published_display": "03 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) CEO shares withheld to cover RSU tax obligations", "summary": "Jazz Pharmaceuticals' President & CEO, Renee D. Gala, had 4,835 ordinary shares withheld on June 30, 2026, to cover tax obligations from vested restricted stock units. This was a tax-withholding disposition at $237.72 per share, not an open-market sale. Following this transaction", "url": "https://www.stocktitan.net/sec-filings/JAZZ/form-4-jazz-pharmaceuticals-plc-insider-trading-activity-f1eac915221a.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:40:35", "published_display": "02 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) EVP reports RSU tax withholding and retains 47,911 shares", "summary": "Jazz Pharmaceuticals' EVP and Chief Commercial Officer, Samantha Pearce, reported a tax-related disposition of 2,527 ordinary shares at $237.72 per share to cover tax obligations arising from the vesting of restricted stock units. This was a non-market transaction for tax withhol", "url": "https://www.stocktitan.net/sec-filings/JAZZ/form-4-jazz-pharmaceuticals-plc-insider-trading-activity-c9f9e4413cb1.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:09:18", "published_display": "02 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) insider RSU tax withholding detailed", "summary": "Jazz Pharmaceuticals' EVP & Chief Legal Officer, Neena M. Patil, had 2,678 ordinary shares withheld on June 30, 2026, to cover tax obligations arising from the vesting of restricted stock units (RSUs). This transaction, valued at $637,000 based on a reference price of $237.72 per", "url": "https://www.stocktitan.net/sec-filings/JAZZ/form-4-jazz-pharmaceuticals-plc-insider-trading-activity-d8762d7028e1.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:09:18", "published_display": "02 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) CFO reports 3,343-share tax withholding", "summary": "Jazz Pharmaceuticals' EVP & CFO, Philip L. Johnson, reported a tax-withholding transaction where 3,343 ordinary shares were withheld at $237.72 per share to satisfy tax obligations on vesting restricted stock units. After this, he directly holds 56,431 shares. Additionally, Johns", "url": "https://www.stocktitan.net/sec-filings/JAZZ/form-4-jazz-pharmaceuticals-plc-insider-trading-activity-27264bf2c2a8.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:40:35", "published_display": "02 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Price Forecast: Will Breakout Confirm Higher Highs?", "summary": "Jazz Pharmaceuticals (JAZZ) has confirmed a bull flag breakout, with its stock closing above $243.32, reinforcing a long-term bullish trend. The stock's price activity indicates a higher swing low and successful test of the 50-day moving average, suggesting further upside potenti", "url": "https://www.fxempire.com/forecasts/article/jazz-pharmaceuticals-jazz-price-forecast-will-breakout-confirm-higher-highs-1608129", "source_name": "FXEmpire", "published_at": "2026-07-02T20:40:35", "published_display": "02 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals stock hits all-time high at 243.39 USD", "summary": "Jazz Pharmaceuticals (JAZZ) stock has reached an all-time high of $243.46, trading just below its 52-week high of $243.32, marking a 132% surge from its 52-week low. This strong performance, reflected in a 121.3% one-year change, is supported by the company's impressive 91.5% gro", "url": "https://www.investing.com/news/company-news/jazz-pharmaceuticals-stock-hits-alltime-high-at-24339-usd-93CH-4774009", "source_name": "Investing.com", "published_at": "2026-07-02T20:09:18", "published_display": "02 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals stock hits all-time high at 243.39 USD By Investing.com", "summary": "Jazz Pharmaceuticals (JAZZ) stock has reached an all-time high of $243.46, trading just below its 52-week high, marking a 132% surge from its 52-week low. Despite this impressive performance, InvestingPro analysis suggests the stock remains undervalued, highlighting a strong gros", "url": "https://ca.investing.com/news/stock-market-news/jazz-pharmaceuticals-stock-hits-alltime-high-at-24339-usd-93CH-4718882", "source_name": "Investing.com Canada", "published_at": "2026-07-02T19:40:35", "published_display": "02 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bruce Cozadd files Form 144 to sell shares \u2014 Jazz Pharmaceuticals (NASDAQ: JAZZ)", "summary": "Jazz Pharmaceuticals (NASDAQ: JAZZ) director Bruce Cozadd has filed a Form 144 to sell shares, detailing recent dispositions of 6,000 shares on three separate dates in 2026 (April 1, May 1, and June 1). The filing also shows previously issued stock options from 2018 and 2019. Thi", "url": "https://www.stocktitan.net/sec-filings/JAZZ/144-jazz-pharmaceuticals-plc-sec-filing-76333d174019.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:11:16", "published_display": "01 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Jazz Pharmaceuticals Plc For: 1 July By Investing.com", "summary": "This article announces the filing of Form 144 by Jazz Pharmaceuticals Plc for July 1. It is a brief financial news update from Investing.com. The content provided is primarily metadata and navigational information, indicating a simple notice of a regulatory filing.", "url": "https://ca.investing.com/news/stock-market-news/form-144-jazz-pharmaceuticals-plc-for-1-july-93CH-4716880", "source_name": "Investing.com Canada", "published_at": "2026-07-01T20:11:16", "published_display": "01 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Jazz Pharmaceuticals plc \u2013 NASDAQ:JAZZ", "summary": "This article provides financial data for Jazz Pharmaceuticals plc (NASDAQ: JAZZ), focusing on its forward price-to-earnings ratio. It indicates that the market is closed and no trades were made, with the period value and changes left blank. The content", "url": "https://www.tradingview.com/symbols/NASDAQ-JAZZ/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T14:39:35", "published_display": "01 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Stock Gets Fair Value Boost As Ziihera Views Split Analysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxObmdHOEJlZkh5RVZoYlhHcW5QbUFSWVM1T2Y2NTc2V0JQVTItay1EYzV2SXVDWjFOcUtNOHJSQVFoVTlXX0pYWnJUMUt1eTdCS0ZiYnE1eENidWQ4eEhkdHVfSUNnRGdYV3pSZHJ5OXZjbDRlTVRkRXdOYWZOSXJLTEFwck9naVQyN1lMQ2pCbkNDUVFHVHlvLU1qaG9zazFoRWVJ?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwJBVV95cUxQYkFXcXJKVlRaaVVzenFqM3JFMkNsSkxCQnhsVlRzRUFfaEtFOFdMRjJFUTJleEFLYlJHVTRvYm9EdGxhMFZEN2QyRVNWQkZoM2FEMW04aV82WHRkZEM5Z2lqMGpicThtcjNScGhnU3kybGtiRmxjZjZiX0RNb202SmloUE1NUVhCczJ2VFkzblBjR1ZVc0xCdV83WHV2NGZ5VUhaTUtpeUpndVpmd3hDSFZ6TDVOMTd1d3BsbGpkTUFtUjRwbjNXZGxFY3dreXNobUpzNnBvQ0FQUUlVa1RDZ2FLRVZqcm0xQm9Pc1VFQ2l1Ti1jdUVJbGo0T0pnOWg1SlVaVEdWMnNXNHZ6ZFNB?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia", "summary": "", "url": "https://news.google.com/rss/articles/CBMikANBVV95cUxPSnF4LTdJYXJlSHdoN3JNM2pEdmZIWjY3NHdxTVpYZERkVDhkTTZfaUZ1LWI5Q2hlWTJxMm5uaDRyQ0ZzYzZ2N2JDRzQ4bXZPcmxKNF9pRjVZUkhzUXFpQXEyelVybG5mdFdjYlBUb2YtZm1oZEZLTzhVWnZnSTNOYjIwa19LREk5YkMteXZ4ZmswWFdDeHYwckZtWi1qQ3VhUUFTV0lPOHFpdW5qRUVTTlZhSEtwMWFRNmVvb05vbjNvQmhPS1d6SWJpOHZ2b196ZC1TLVM0NkNvLWZLVUFUNFhHVDRMTG1jczEtN24wcjhNX1JzUkZBeEZoZ0hqSVFmMGJoYUFqcjhySUdMYnJ5SmZhVWJmWmdIaHQwTUZTcFhFYmlMT0FDNXZETVZtMC1ydXdaTkhsSktySzVweTB1LXRLTDZEMEg3Nlh3X2VFOVFUcHY4WW1ZN19WS1hLY0N2NlMzb3UwUTRzZGZqOFZoVXJMc2lwNVdJN2trQnR5dEFBQ2t4V05ZUFdpeHF0aERp?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPZzk1UXlacFlpa05uSS1wTmR2emZtOTN3eURSM2RMNm9RRzRNZ3ZtNHZEaXZ3R2pJYnJtRlJJck43bmdjV2lyTFhBbUFwLUhyTkl2REcyRU9yVnh3cUNETkN5RzRXTmFfTUdkaW85eUZROEM0eV8ycG9ucXpLd3ZGaTZaVmcxUHNwVzZLVDB1bWwzM0pSWGg0R3VLV1lXWlR5?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals Provides Update on Zepzelca\u00ae (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAJBVV95cUxQY0Rzb25hY0xUUW5raEduRnViZUtiRERxU2JLRVFhYWxLMW5jaTlVWlhhUnY4Q1J6MFlaQmpiLU5IMGlhYmRBR0had0g4RHNZY214TDVQSXZzV3l0cTdHWlU1amxzWXRZN0JUNERvMlQtc1lubTNUVW03bUc0RmJoc2ZwWVpFTjdaY0hYeWhrYjRoRU8tMUJnREVvZFBBa1RpeXFsMjMtRy1HdjZUMm13eTctZllHLW14QS1lSmJHcldidHhkaDNvM2lRR09WLTlLNU1EdHU1ZldIVG54ZHlzM0wtV0F3OVhDSVI2dTlrLWdtMTFHeExTTV9XdmtDY2h6b2ZpNmRkdkw?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Cigna (CI), Jazz Pharmaceuticals (JAZZ) and Lifestance Health Group (LFST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwJBVV95cUxPQXF4NV9OMWszY0ROai1UN0laSnFvaERvSHREY1BxU1lRaVhUb1NwQ0RhOHk2Y2R4c0lTb3FvTFQxMDhRaEU2OGVQTTFsQ3RHZVBVYlhub2VYMjE1d2M2Z3ZkUjVqYnVZS3dvdjgyeEliMmxxWS1qRmZNanZyb3p6UE50QWtReC1Sc3p2Wk1fcXUzV0xNdV9DZlBHWXlIQTlQd3FqdG1SQ2ltYkVLTDJSYURteVRMaUJKeUc1eFlZT1NNdzFVTElwV0M2NDhQbVpEYTVOSy1WdHpLOUhBM1BycWFFcGNxTEk0SWFWRjJ1VEdEMmVWaDZnQWxxcGxDZFZCbjlCN3JfWlJZUVpSM2NuZVEyR0tnS1VndXZRcDR3VmdSSnlRTFA0?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Raises its Price Target on Jazz Pharmaceuticals (JAZZ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxObkNHazlhaVQ0R3lzM2prTGtnbE1MdEZpVEZFWHFTX24xNTFtaEM5bHJnd0VWaU8xX005RkhMR3RXMWNyTDBwTlYyVDZpaVpfcHFRYjNSS2pqb0VhNE03ck9wUElibnZobmliZlNQZ3dNRUwyS0kteDdUYkltclBDd000M3BnRzlnQjNBUnE1Q3JCOTgzRFMxSUVEMlZyZXFfMXY5UHJn?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Its Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPdldFT3FBRGJSYnAwZkh0dGM4bHYtbEY3UGpOb2lYQy05blhXSTBtU3BPZnFuQW5zYzF6WGsweXlMaGZnY0o2Uzg3QTJxMlJwOXFidU1EcG1abGxBMkV5XzlMVURmU0hOd0NFNlFsci1sRUhYZG9ST2xkd0dydlN4Yy1XeHNFZVdNQzA5NlJyck1WLTdxMmF0YnRNOVMtblFWTUxjd3k4TWl3UzREdTdZ?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here Are Tuesday\u2019s Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgJBVV95cUxQX3JtcDlyQXN1aHdhUVMwcm9xZmR0dnJkaVhjeHdjZkRTOUVQVjhmeHRfMWs3aS0tM1pJM0EtZHFXdVI2U2dDVktPWVdPN1Z6YWtadjRVMGJPcmh6THdUOTlSX0Q4bVVVY2RIQnVBbWQzQ2kwVU9kQXdkWFhOLWFzTjZlTTdqU1daZ2hrTGtCTkc4WDBsajU0dGRrV05va2U5RE1KOWMxTFZXYkNMZHAzS2NPb1k4emJ3MDRDOVhqQlVveTJLTWlsZEtFWjNORlZqQ3l5ZmI1ZkRZVUxfSTdZV3QtbkM2TFZZWVlQUDJyVVFNQnoxcUl6NUMxcEdIcDNsbHhaTmpDcjBobkpyTUlfOHlHa1V0dUxkaFctV29GbzdxMXFIeG8yV0tIOTNYTXRaamFtdS1R?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "We Think You Can Look Beyond Jazz Pharmaceuticals' (NASDAQ:JAZZ) Lackluster Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Jazz Pharmaceuticals plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals Stock Surged 105% Over the Past Year. Here\u2019s What\u2019s Driving the Move", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOSHFwenh4RGFndngtR3lkV1dsalBHLVVfYmJldjBlWXVnS2V4TTV6enBjOUVNNzBpZDlUSC1Sc2pnVzBuWTlGZ0JVbk0tQy1CV3NOdk9Pdkt5WDQ5NjY1UjFGVHh5QzZOU3BaV3ZCam9ZLVB6cV80RjQybXd4aVR0SU04TEVWSm45d08yN0xZaGRzNF9ZTVlBMDctZVVyd21acGd3dUdBUS1yX0xXd0NXVw?oc=5", "source_name": "TIKR.com", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Q1 EPS Rebound Tests Bearish Margin Narratives", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPcGcyOG1JWDZ2bDM1SExnbkJfdXl3ZkMzUWVveU90NVpPak90QUpKWjJvSkduSzU3NlJJc3ZhRHhRRFJ5MUpxZVRaNkZldHM2b2xWV0pZSmczUklhMDhKSDhjS184WTNnY0NFT1E5TEVuRnZQbGstSjFfZEtjZzc3M2Q0WG8yc09lNkJFc2wtUDhCTXVFcF8yT0ZkM09qOVVvMzJibFp3MFBtOXZZa19IVmtIZFBVYTJfQmxMSjVCdEdBT0xMY2FLYUp6Y3UyRzJSaUZJYjY1eHRHaG5PWlViV2F3VTJZRmdhRlHSAe8BQVVfeXFMUG02UFJMbElDLWtGb0lFRmMySTVMVkVSSnkxR0w0MzVvd1JycmdWSUxydThWdlI3Rkk4SERUSVRBY3BNU3c4R2cwUzFVT0RQZ0t5Y0g1dlRJakVGZFY0ZDRpTHdGbU9PTTlsd2lMbWYycDQ5RmpXWHdneHNCaC02ajhtaTl0a1hFR0ZJVTZlUnBKQ3NaamZpblBfbTlaNjFmZk5VVlpfY2l1RnBvTk84Xzl4RHNyZmJneW1rUVBCaWNNN1pfVjg1b3FUTDJtY3ByUWZrT1lBTTlfQkNYdzhMb0U0UE0wSFFaNDdaejhhc2c?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQZnluNWVldDd5bDFkVHczZ0FDa1d6NXJ1VXd6eFZVT0E2d1JVbWRDakp0NTJEeS14bXkybVcxVlBTZy1uUXpDZno0aDk4Q2FRT1BmZ0h2cGpsbXo1Z0Jna2liOWZCaW5SZjRoZXJFN2laZ1VEb0h6Ul9fbERKRkZJOTJVSXFpLXZBcFI2VjF5cGxGUVEyNXFVRUhoTzdHaFFmNmFFZXNtU0gtNU1LaThZR2ZIUEpRV0t2S0lvTHlPUkc?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Too Late To Consider Jazz Pharmaceuticals (JAZZ) After A 93% One Year Rally?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgJBVV95cUxQUTl5NE1hcXB3djJKRmZSelM0YUhKbXNyXy1zbWpwTlRjQlBINWNZOVVCbUJDWjFjMnFLS2FneFp4UE52MTNXR0ZwaktlaEFDaXNzM09CcDd6LXBvSWxiZ2tvQVJudlo5aVdSSVUydUFlcUFRa3h5QnY5eS1iejNRN0I4UzJIOHlGMGlLX21MczhDYjkyNDB1NzJjQzNrRTl2aFpOYTlLMDR4b1JjWlhXelZmUVlWRS1zQnpCLTBsczZyb2FDYmk1aHRuSE1jMjFrV3h3eExfalRvb0RwREh5djNRTC01WHF3T2V3ZUVwVnZqQk14emFjTEdyZ3FKRFZCWVVpM2dn?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Who Owns Jazz Pharmaceuticals? Top Shareholders and Recent Insider Trades", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQVElHQXlXOGRHTkdHNU1pdXpGNjJXLXFjVjYybXAwbGU2eXBtb1pxMHppRkpYUWV6WnhHRTNIa2tiUTNVTUJNR09WMFQ4eG5nZFptRVhVcDZBcnBMbDF0Y1FwYmR4aGhBWXI0S2hrVjNRcklIcWVjcWdhaXJSWFJ0QUlWNUxlSVo5WVZUbDZFNG13M2h0VUFKQmZCd1FYX2s?oc=5", "source_name": "TIKR.com", "published_at": "2026-01-02T08:00:00+00:00", "published_display": "02 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Improved Revenues Required Before Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 25% Jump Looks Justified", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNamxjZGNLSnFGeDdXcTZETTlyWk9vNXRuVTljTzd3ODNXcmkwXzVkRUo1SnVmUXdBUkNuZ245SUZMWEZFTjdSUWZpSDVzaE5pRkFMM2RLQjhnTlBpbXdiZkRBeWIxWlhLTDBNT0NHUGdTOTg5b3hGUnJ6cDZSX3hxcjRTMnFwTGs5dWUyTTI5djgxSWNPbHA2VU9teVNOR3F1RllqbFNzeUhrSmJuZmZKSy1LRFUzYnRxM05nZFFpbDFlMDNPelFTNEE0VE5oRWJzY1Z0RmxoS1VFVlR4TFBxbVlTeXZKUVM4QmfSAe8BQVVfeXFMUDh2cWlyUW1DdVQtVW9SY29ZdzdoQjRfbFVUeGxONDgyQ09UZUNOekVkS3hqYVpSZXBOa2VOYThXNi1lcFJXMXZueWdkY2FRb25tQ0tESkk4a2NQSktqaGNoaHN2c1BncTgwZlZTd0JXeVFyTEM1TVdWZmZFWTV4dmt0bnM4SVY5SWtRbVB1cDcwajdBVVpQR0ppSUFJSHZSUTRXRmk3LUJ5dzFZeGJ5VnN1TmZuZXpSZlRrYjEydE96VFh5UGtQS1VlUWRTU2NHLUVHMWhTcFFHblV4TGxzYklkN0FUZTVTMDVwUlBZck0?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso\u2122 (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwJBVV95cUxPdkpJZkE3TUNxVzBrd0xEUFVuUnJ3YTVjUHQ0cUVwUGpNN2ZuX2hTVU1UWFZ3TUNJRl9ScUc3ZDZieVB4UFpXNGVsbXBCRjM3eFdEWnI2Tzd3UEQ0OTFPU0ZCZGc5VTJTMGV6aEgyM2h1bm1qbExKb3d1Z3BDZ3FVWW1JaV9ZNlZqMkRCR2JpbnJiaVNlb1pGTFJqRzg4OU1vVVF1amZpM1Q4TGk1ZFlYVzdmZWx5Wnk0V3hFb2h5b3pVRWllN2c5MC03N254UWZOSDZVQ3NUZmhCS2UwYjdVXzJaaml6Q0s4alZ0U0ZObGVNT084TjRWNWdQMGhIMjJua3MyM2wyT2lYRk9Qb1BmVk5qRU40aHJCekRnUjRFQUlDblFnbmhZ?oc=5", "source_name": "PR Newswire", "published_at": "2025-11-11T08:00:00+00:00", "published_display": "11 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Jazz Pharmaceuticals stock hits all-time high at 250.85 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNOVU2TzNESXpsc01pZWw0NUlHVVUteXVQZmZiMnUwZ3h3QTlmR1BMZVFlcEo5aVdTTzBDZ1A1ZU1wNzBENXpBSEU4dEZHd2E5TXMtLWRPNGF6N3pzbmdlYTlOWm9sZEcybVptZS1ranV3c1pZMjRoVDl1ZTFmTE1BcnhBcXZUQTJKdk5EUXB4bFBRd1V0eEt6UUhpdXlCYzlUdHl5MWNqZTEyenZZSGgxVVptYy0?oc=5", "source_name": "Investing.com", "published_at": "2026-07-21T16:38:54+00:00", "published_display": "21 Jul 2026 16:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals sets Aug. 3 webcast after market close", "summary": "Jazz Pharmaceuticals (Nasdaq: JAZZ) announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close of U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to review results and provide a business and financi", "url": "https://www.stocktitan.net/news/JAZZ/jazz-pharmaceuticals-to-report-second-quarter-financial-results-on-7yj4racuhw9r.html", "source_name": "Stock Titan", "published_at": "2026-07-20T20:18:23", "published_display": "20 Jul 2026 20:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026", "summary": "Jazz Pharmaceuticals plc announced it will report its second-quarter 2026 financial results on Monday, August 3, 2026, after the close of U.S. financial markets. The company's management will host a webcast at 4:30 p.m. ET to discuss the results and provide business and financial", "url": "https://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-to-report-second-quarter-financial-results-on-august-3-2026-302829880.html", "source_name": "PR Newswire UK", "published_at": "2026-07-20T20:15:23", "published_display": "20 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Jazz\u2019s Sleep and Oncology Pipeline Momentum Just Shift Jazz Pharmaceuticals' (JAZZ) Investment Narrative?", "summary": "Jazz Pharmaceuticals is gaining investor attention due to its sleep-disorder and oncology portfolios, particularly with progress in its pipeline and franchise positioning. The company's investment narrative depends on its ability to leverage these franchises to offset patent clif", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/did-jazzs-sleep-and-oncology-pipeline-momentum-just-shift-ja/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-19T19:40:32", "published_display": "19 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Q1 2026 earnings summary", "summary": "Jazz Pharmaceuticals (JAZZ) reported record Q1 2026 revenues of $1.1 billion, a 19% year-over-year increase, driven by strong growth in its sleep, epilepsy, and oncology portfolios. The company achieved a net income of $293.1 million, a significant improvement from a Q1 2025 net ", "url": "https://quartr.com/events/jazz-pharmaceuticals-jazz-q1-2026_oC4svVf7", "source_name": "Quartr", "published_at": "2026-07-19T02:11:12", "published_display": "19 Jul 2026 02:11", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Stock Still Looks Like A Bargain After A 119% Run", "summary": "Jazz Pharmaceuticals (JAZZ) has seen a significant 119.3% return over the past year, prompting an evaluation of its current valuation. Despite this strong performance, Simply Wall St's analysis suggests the stock appears undervalued on several measures, trading at a P/S ratio (3.", "url": "https://uk.finance.yahoo.com/news/jazz-pharmaceuticals-jazz-stock-still-111411652.html", "source_name": "Market source", "published_at": "2026-07-18T11:09:29", "published_display": "18 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Refocuses Its Sleep Franchise, Is The Stock Still Cheap?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPbGNyTjRDemN6U21hcXVmaXc1Qk81YmhvSENud09RbHRoWURIVk1kTWI3dlBSNW1SUlhHUmttZmRGcllucElnMTVqZ091ZEJiS3dicW4wdVFnekVxWG9MSUdrZ3Q4WkQ0azBjSHBkMl93Q0VsdnB1eHI5aUh0T1Q5UzVTbTVsUEpLVmtaTlhONE9DdldGVU5oU0Y0RV9wR1pnQkxzVQ?oc=5", "source_name": "Market source", "published_at": "2026-07-18T07:11:42+00:00", "published_display": "18 Jul 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Upgrades Jazz Pharmaceuticals(JAZZ.US) to Buy Rating, Announces Target Price $290", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQNWs1MkVrRUdLZ25EckhQaGdZaVNTSDBxb3QtZEVMWERSNFQ4aEpLZkkycGY3TFNBcTZqeHRWb1VNQ2pPakZJTkNuVE52dG9VVEFGbW5jVGtvQThScDNjR09pcmRPMmZBVUJIVWFYSlAwc0NaTUlRejZ6V2psd2lNdXFQbnQwbUJRWHhNRGxQVVFyNG9NNE55NFV5TTN1UDQ1dVZjTW8xbEhlSEltNEpWejNjTEs1dw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-17T16:40:04+00:00", "published_display": "17 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord Genuity Initiates Coverage on Jazz Pharmaceuticals With Buy Rating, $290 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/canaccord-genuity-initiates-coverage-jazz-112031961.html", "source_name": "MT Newswires", "published_at": "2026-07-17T11:20:31+00:00", "published_display": "17 Jul 2026 11:20", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JAZZ PHARMACEUTICALS PLC : CANACCORD GENUITY INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $290", "summary": "Canaccord Genuity has initiated coverage on Jazz Pharmaceuticals PLC (JAZZ.O) with a \"BUY\" rating. The firm has set a target price of $290 for the company's shares. This report originated from Reuters and was published on July 17, 2026, at 04:40.", "url": "https://www.bitget.com/asia/news/detail/12560605512956", "source_name": "Bitget", "published_at": "2026-07-16T20:39:53", "published_display": "16 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 94, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Jazz Pharmaceuticals (JAZZ) Still Undervalued On Its Oncology And Neuroscience Growth Story?", "summary": "Jazz Pharmaceuticals (JAZZ) has shown strong share price performance and revenue growth, leading to a narrative that pegs it as 7.4% undervalued with a fair value of $257.00. This optimism stems from the expected approval and launch of new therapies, particularly within its oncol", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/is-jazz-pharmaceuticals-jazz-still-undervalued-on-its-oncolo/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-15T00:45:30", "published_display": "15 Jul 2026 00:45", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Q4 2025 earnings summary", "summary": "Jazz Pharmaceuticals reported record total revenue of $4.3 billion in 2025, a 5% increase year-over-year, with Q4 revenue reaching $1.2 billion, up 10%. Three of its franchises\u2014rare sleep, rare epilepsy, and rare oncology\u2014each surpassed $1 billion in annual revenue. The company a", "url": "https://quartr.com/events/jazz-pharmaceuticals-plc-jazz-q4-2025_oC4sJU67", "source_name": "Quartr", "published_at": "2026-07-12T20:40:32", "published_display": "12 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Q1 2025 earnings summary", "summary": "Jazz Pharmaceuticals (JAZZ) reported Q1 2025 revenues between $897.8M and $902M, driven by strong growth in Xywav and Epidiolex, despite declines in oncology and Xyrem. The company affirmed its 2025 revenue guidance of $4.15\u2013$4.4 billion and expects Epidiolex to achieve blockbust", "url": "https://quartr.com/events/jazz-pharmaceuticals-plc-jazz-q1-2025_oC4sJPF0", "source_name": "Quartr", "published_at": "2026-07-10T07:13:02", "published_display": "10 Jul 2026 07:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JAZZ Maintained by Deutsche Bank -- Price Target Raised to $270", "summary": "Deutsche Bank has maintained a 'Buy' rating on Jazz Pharmaceuticals (JAZZ) and raised its price target from $250 to $270, indicating an 8% projected increase. Despite this positive analyst outlook, GuruFocus data suggests JAZZ is significantly overvalued by 63.5% based on its GF ", "url": "https://www.gurufocus.com/news/8952212/jazz-maintained-by-deutsche-bank-price-target-raised-to-270", "source_name": "GuruFocus", "published_at": "2026-07-09T21:10:50", "published_display": "09 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Status Update Summary", "summary": "Jazz Pharmaceuticals' (JAZZ) Phase III IMforte trial demonstrated significant improvement in progression-free survival and overall survival for extensive-stage small cell lung cancer patients treated with lurbinectedin plus atezolizumab. This regimen is now positioned as a potent", "url": "https://quartr.com/events/jazz-pharmaceuticals-plc-jazz-status-update_oC4sJANL", "source_name": "Quartr", "published_at": "2026-07-09T06:10:25", "published_display": "09 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Q4 2024 earnings summary", "summary": "Jazz Pharmaceuticals achieved record total revenues of $4.1 billion in 2024, a 6% year-over-year increase, with Q4 revenue reaching nearly $1.1 billion. Key growth drivers included Xywav and Epidiolex, and the company made significant progress in its R&D pipeline with FDA approva", "url": "https://quartr.com/events/jazz-pharmaceuticals-plc-jazz-q4-2024_oC4sldIq", "source_name": "Quartr", "published_at": "2026-07-09T05:41:26", "published_display": "09 Jul 2026 05:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Q3 2024 earnings summary", "summary": "Jazz Pharmaceuticals reported record Q3 2024 revenues of $1.05 billion, a 9% year-over-year increase, driven by strong sales of Xywav, Epidiolex, and Zepzelca. Net income rose significantly to $215.1 million, with adjusted EPS increasing by 37% to $6.61. The company affirmed its ", "url": "https://quartr.com/events/jazz-pharmaceuticals-plc-jazz-q3-2024_oC4slb3e", "source_name": "Quartr", "published_at": "2026-07-09T05:41:26", "published_display": "09 Jul 2026 05:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Jefferies Global Healthcare Conference Summary", "summary": "Jazz Pharmaceuticals shared an event summary from the Jefferies Global Healthcare Conference on July 8, 2026, highlighting significant progress in commercial activities, R&D, and corporate development, including the integration of Zymeworks and zanidatamab. The company provided a", "url": "https://quartr.com/events/jazz-pharmaceuticals-plc-jazz-jefferies-global-healthcare-conference_oC4sv3Rx", "source_name": "Quartr", "published_at": "2026-07-09T05:10:50", "published_display": "09 Jul 2026 05:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks", "summary": "This article lists various ETFs that hold stocks of Jazz Pharmaceuticals Public Limited Company (JAZZ/N), providing details like market value, weight, issuer, management style, focus, expense ratio, AUM, price, and 3-year NAV total return for each fund. The ETFs listed range acro", "url": "https://www.tradingview.com/symbols/BIVA-JAZZ/N/etfs/", "source_name": "TradingView", "published_at": "2026-07-08T12:10:30", "published_display": "08 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) director Cozadd sells 6,000 shares via 10b5-1 trade", "summary": "Jazz Pharmaceuticals plc director Bruce C. Cozadd reported an open-market sale of 6,000 Ordinary Shares of JAZZ on July 1, 2026, at an average price of $240.47 per share, totaling $1.44 million. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted ", "url": "https://www.stocktitan.net/sec-filings/JAZZ/form-4-jazz-pharmaceuticals-plc-insider-trading-activity-ce06590bf5ed.html", "source_name": "Stock Titan", "published_at": "2026-07-07T17:39:59", "published_display": "07 Jul 2026 17:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JAZZ - Jazz Pharmaceuticals plc Options", "summary": "This article provides a detailed financial overview of Jazz Pharmaceuticals plc (JAZZ), including its last closing price, market capitalization, key financial ratios, EPS and sales growth rates, and various performance metrics. It also lists insider and institutional ownership, p", "url": "https://finviz.com/stock?t=JAZZ&ta=1&p=m&ty=oc&r=max&ov=list_strike&s=250", "source_name": "Finviz", "published_at": "2026-07-03T15:10:41", "published_display": "03 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Breakout Keeps Valuation In Focus Following Zepzelca Setback And Ziihera Hopes", "summary": "Jazz Pharmaceuticals (JAZZ) stock has broken out of a long-term trading base near an all-time high, driven by mixed news regarding its cancer drug Zepzelca and optimism surrounding Ziihera. Despite a 122.45% 1-year return, the company is considered 5.3% undervalued, with a fair v", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/jazz-pharmaceuticals-jazz-breakout-keeps-valuation-in-focus/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-03T02:09:18", "published_display": "03 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) CEO shares withheld to cover RSU tax obligations", "summary": "Jazz Pharmaceuticals' President & CEO, Renee D. Gala, had 4,835 ordinary shares withheld on June 30, 2026, to cover tax obligations from vested restricted stock units. This was a tax-withholding disposition at $237.72 per share, not an open-market sale. Following this transaction", "url": "https://www.stocktitan.net/sec-filings/JAZZ/form-4-jazz-pharmaceuticals-plc-insider-trading-activity-f1eac915221a.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:40:35", "published_display": "02 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) EVP reports RSU tax withholding and retains 47,911 shares", "summary": "Jazz Pharmaceuticals' EVP and Chief Commercial Officer, Samantha Pearce, reported a tax-related disposition of 2,527 ordinary shares at $237.72 per share to cover tax obligations arising from the vesting of restricted stock units. This was a non-market transaction for tax withhol", "url": "https://www.stocktitan.net/sec-filings/JAZZ/form-4-jazz-pharmaceuticals-plc-insider-trading-activity-c9f9e4413cb1.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:09:18", "published_display": "02 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) insider RSU tax withholding detailed", "summary": "Jazz Pharmaceuticals' EVP & Chief Legal Officer, Neena M. Patil, had 2,678 ordinary shares withheld on June 30, 2026, to cover tax obligations arising from the vesting of restricted stock units (RSUs). This transaction, valued at $637,000 based on a reference price of $237.72 per", "url": "https://www.stocktitan.net/sec-filings/JAZZ/form-4-jazz-pharmaceuticals-plc-insider-trading-activity-d8762d7028e1.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:09:18", "published_display": "02 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) CFO reports 3,343-share tax withholding", "summary": "Jazz Pharmaceuticals' EVP & CFO, Philip L. Johnson, reported a tax-withholding transaction where 3,343 ordinary shares were withheld at $237.72 per share to satisfy tax obligations on vesting restricted stock units. After this, he directly holds 56,431 shares. Additionally, Johns", "url": "https://www.stocktitan.net/sec-filings/JAZZ/form-4-jazz-pharmaceuticals-plc-insider-trading-activity-27264bf2c2a8.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:40:35", "published_display": "02 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Price Forecast: Will Breakout Confirm Higher Highs?", "summary": "Jazz Pharmaceuticals (JAZZ) has confirmed a bull flag breakout, with its stock closing above $243.32, reinforcing a long-term bullish trend. The stock's price activity indicates a higher swing low and successful test of the 50-day moving average, suggesting further upside potenti", "url": "https://www.fxempire.com/forecasts/article/jazz-pharmaceuticals-jazz-price-forecast-will-breakout-confirm-higher-highs-1608129", "source_name": "FXEmpire", "published_at": "2026-07-02T20:40:35", "published_display": "02 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals stock hits all-time high at 243.39 USD", "summary": "Jazz Pharmaceuticals (JAZZ) stock has reached an all-time high of $243.46, trading just below its 52-week high of $243.32, marking a 132% surge from its 52-week low. This strong performance, reflected in a 121.3% one-year change, is supported by the company's impressive 91.5% gro", "url": "https://www.investing.com/news/company-news/jazz-pharmaceuticals-stock-hits-alltime-high-at-24339-usd-93CH-4774009", "source_name": "Investing.com", "published_at": "2026-07-02T20:09:18", "published_display": "02 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals stock hits all-time high at 243.39 USD By Investing.com", "summary": "Jazz Pharmaceuticals (JAZZ) stock has reached an all-time high of $243.46, trading just below its 52-week high, marking a 132% surge from its 52-week low. Despite this impressive performance, InvestingPro analysis suggests the stock remains undervalued, highlighting a strong gros", "url": "https://ca.investing.com/news/stock-market-news/jazz-pharmaceuticals-stock-hits-alltime-high-at-24339-usd-93CH-4718882", "source_name": "Investing.com Canada", "published_at": "2026-07-02T19:40:35", "published_display": "02 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bruce Cozadd files Form 144 to sell shares \u2014 Jazz Pharmaceuticals (NASDAQ: JAZZ)", "summary": "Jazz Pharmaceuticals (NASDAQ: JAZZ) director Bruce Cozadd has filed a Form 144 to sell shares, detailing recent dispositions of 6,000 shares on three separate dates in 2026 (April 1, May 1, and June 1). The filing also shows previously issued stock options from 2018 and 2019. Thi", "url": "https://www.stocktitan.net/sec-filings/JAZZ/144-jazz-pharmaceuticals-plc-sec-filing-76333d174019.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:11:16", "published_display": "01 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Jazz Pharmaceuticals Plc For: 1 July By Investing.com", "summary": "This article announces the filing of Form 144 by Jazz Pharmaceuticals Plc for July 1. It is a brief financial news update from Investing.com. The content provided is primarily metadata and navigational information, indicating a simple notice of a regulatory filing.", "url": "https://ca.investing.com/news/stock-market-news/form-144-jazz-pharmaceuticals-plc-for-1-july-93CH-4716880", "source_name": "Investing.com Canada", "published_at": "2026-07-01T20:11:16", "published_display": "01 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Jazz Pharmaceuticals plc \u2013 NASDAQ:JAZZ", "summary": "This article provides financial data for Jazz Pharmaceuticals plc (NASDAQ: JAZZ), focusing on its forward price-to-earnings ratio. It indicates that the market is closed and no trades were made, with the period value and changes left blank. The content", "url": "https://www.tradingview.com/symbols/NASDAQ-JAZZ/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T14:39:35", "published_display": "01 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Stock Gets Fair Value Boost As Ziihera Views Split Analysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxObmdHOEJlZkh5RVZoYlhHcW5QbUFSWVM1T2Y2NTc2V0JQVTItay1EYzV2SXVDWjFOcUtNOHJSQVFoVTlXX0pYWnJUMUt1eTdCS0ZiYnE1eENidWQ4eEhkdHVfSUNnRGdYV3pSZHJ5OXZjbDRlTVRkRXdOYWZOSXJLTEFwck9naVQyN1lMQ2pCbkNDUVFHVHlvLU1qaG9zazFoRWVJ?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwJBVV95cUxQYkFXcXJKVlRaaVVzenFqM3JFMkNsSkxCQnhsVlRzRUFfaEtFOFdMRjJFUTJleEFLYlJHVTRvYm9EdGxhMFZEN2QyRVNWQkZoM2FEMW04aV82WHRkZEM5Z2lqMGpicThtcjNScGhnU3kybGtiRmxjZjZiX0RNb202SmloUE1NUVhCczJ2VFkzblBjR1ZVc0xCdV83WHV2NGZ5VUhaTUtpeUpndVpmd3hDSFZ6TDVOMTd1d3BsbGpkTUFtUjRwbjNXZGxFY3dreXNobUpzNnBvQ0FQUUlVa1RDZ2FLRVZqcm0xQm9Pc1VFQ2l1Ti1jdUVJbGo0T0pnOWg1SlVaVEdWMnNXNHZ6ZFNB?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPZzk1UXlacFlpa05uSS1wTmR2emZtOTN3eURSM2RMNm9RRzRNZ3ZtNHZEaXZ3R2pJYnJtRlJJck43bmdjV2lyTFhBbUFwLUhyTkl2REcyRU9yVnh3cUNETkN5RzRXTmFfTUdkaW85eUZROEM0eV8ycG9ucXpLd3ZGaTZaVmcxUHNwVzZLVDB1bWwzM0pSWGg0R3VLV1lXWlR5?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals Provides Update on Zepzelca\u00ae (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAJBVV95cUxQY0Rzb25hY0xUUW5raEduRnViZUtiRERxU2JLRVFhYWxLMW5jaTlVWlhhUnY4Q1J6MFlaQmpiLU5IMGlhYmRBR0had0g4RHNZY214TDVQSXZzV3l0cTdHWlU1amxzWXRZN0JUNERvMlQtc1lubTNUVW03bUc0RmJoc2ZwWVpFTjdaY0hYeWhrYjRoRU8tMUJnREVvZFBBa1RpeXFsMjMtRy1HdjZUMm13eTctZllHLW14QS1lSmJHcldidHhkaDNvM2lRR09WLTlLNU1EdHU1ZldIVG54ZHlzM0wtV0F3OVhDSVI2dTlrLWdtMTFHeExTTV9XdmtDY2h6b2ZpNmRkdkw?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Cigna (CI), Jazz Pharmaceuticals (JAZZ) and Lifestance Health Group (LFST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwJBVV95cUxPQXF4NV9OMWszY0ROai1UN0laSnFvaERvSHREY1BxU1lRaVhUb1NwQ0RhOHk2Y2R4c0lTb3FvTFQxMDhRaEU2OGVQTTFsQ3RHZVBVYlhub2VYMjE1d2M2Z3ZkUjVqYnVZS3dvdjgyeEliMmxxWS1qRmZNanZyb3p6UE50QWtReC1Sc3p2Wk1fcXUzV0xNdV9DZlBHWXlIQTlQd3FqdG1SQ2ltYkVLTDJSYURteVRMaUJKeUc1eFlZT1NNdzFVTElwV0M2NDhQbVpEYTVOSy1WdHpLOUhBM1BycWFFcGNxTEk0SWFWRjJ1VEdEMmVWaDZnQWxxcGxDZFZCbjlCN3JfWlJZUVpSM2NuZVEyR0tnS1VndXZRcDR3VmdSSnlRTFA0?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Raises its Price Target on Jazz Pharmaceuticals (JAZZ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxObkNHazlhaVQ0R3lzM2prTGtnbE1MdEZpVEZFWHFTX24xNTFtaEM5bHJnd0VWaU8xX005RkhMR3RXMWNyTDBwTlYyVDZpaVpfcHFRYjNSS2pqb0VhNE03ck9wUElibnZobmliZlNQZ3dNRUwyS0kteDdUYkltclBDd000M3BnRzlnQjNBUnE1Q3JCOTgzRFMxSUVEMlZyZXFfMXY5UHJn?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Its Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPdldFT3FBRGJSYnAwZkh0dGM4bHYtbEY3UGpOb2lYQy05blhXSTBtU3BPZnFuQW5zYzF6WGsweXlMaGZnY0o2Uzg3QTJxMlJwOXFidU1EcG1abGxBMkV5XzlMVURmU0hOd0NFNlFsci1sRUhYZG9ST2xkd0dydlN4Yy1XeHNFZVdNQzA5NlJyck1WLTdxMmF0YnRNOVMtblFWTUxjd3k4TWl3UzREdTdZ?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here Are Tuesday\u2019s Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgJBVV95cUxQX3JtcDlyQXN1aHdhUVMwcm9xZmR0dnJkaVhjeHdjZkRTOUVQVjhmeHRfMWs3aS0tM1pJM0EtZHFXdVI2U2dDVktPWVdPN1Z6YWtadjRVMGJPcmh6THdUOTlSX0Q4bVVVY2RIQnVBbWQzQ2kwVU9kQXdkWFhOLWFzTjZlTTdqU1daZ2hrTGtCTkc4WDBsajU0dGRrV05va2U5RE1KOWMxTFZXYkNMZHAzS2NPb1k4emJ3MDRDOVhqQlVveTJLTWlsZEtFWjNORlZqQ3l5ZmI1ZkRZVUxfSTdZV3QtbkM2TFZZWVlQUDJyVVFNQnoxcUl6NUMxcEdIcDNsbHhaTmpDcjBobkpyTUlfOHlHa1V0dUxkaFctV29GbzdxMXFIeG8yV0tIOTNYTXRaamFtdS1R?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think You Can Look Beyond Jazz Pharmaceuticals' (NASDAQ:JAZZ) Lackluster Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPS253SFFENXdoVUZGN0Rtdk9Ca2xuTUtwQU1BTGpBNDBseHUzcDdrVl9hOWRxNEN3emt5NE1BMkl2VmRtS3dQbk0zZzRaTmxoRmFfc2ZDT2N0YUVmX0E5WmkxQ0w5Q2dUWFd4aWhwRHFacGpRMVE5ckRDLUNWdlVLZ25PMlBaVGZLMUI4cEZ3MmpEZXUtRlVYSHRjYm5WRjlYM0tlVkFpdnVnV2FENU43cEtCdzV0Y0NnSmc4eXNTWFdHNks1SGZwQVdFWjlpT1FFX21zcXNNNUt3OV9uLUU3U0FIcUVSdGsyOGfSAe8BQVVfeXFMTlJWbzMzNDFZOGJCNTlFcC1oZVVUdGtqNzRUZTY5T3VZOFhEd2VuOFMwSFFhaG90aE5iN0U3c29LeDRoNnFRVm50VWdDU3ZzLVQzNUVwMGxkYmxmUmo1a0dIUXR5cFhUUnVQcG1pZnF0ZFRmblRVRkpKX2VhRXg0blFZeUJnVDRXRENyYW43QXkweTA3LUJRVWx0bUp0c09EV0t3QWdhbWhqX1BxMDlmbERRZm1rUGp6RFY1MEh2UVU2cVk4QkpxQVN5ZWMzRm1yVm1MdzlWellKcm9DQWJ2NUZMbTNWY0h3c0Ntc1JOUjQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals Stock Surged 105% Over the Past Year. Here\u2019s What\u2019s Driving the Move", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOSHFwenh4RGFndngtR3lkV1dsalBHLVVfYmJldjBlWXVnS2V4TTV6enBjOUVNNzBpZDlUSC1Sc2pnVzBuWTlGZ0JVbk0tQy1CV3NOdk9Pdkt5WDQ5NjY1UjFGVHh5QzZOU3BaV3ZCam9ZLVB6cV80RjQybXd4aVR0SU04TEVWSm45d08yN0xZaGRzNF9ZTVlBMDctZVVyd21acGd3dUdBUS1yX0xXd0NXVw?oc=5", "source_name": "TIKR.com", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals (JAZZ) Q1 EPS Rebound Tests Bearish Margin Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQZnluNWVldDd5bDFkVHczZ0FDa1d6NXJ1VXd6eFZVT0E2d1JVbWRDakp0NTJEeS14bXkybVcxVlBTZy1uUXpDZno0aDk4Q2FRT1BmZ0h2cGpsbXo1Z0Jna2liOWZCaW5SZjRoZXJFN2laZ1VEb0h6Ul9fbERKRkZJOTJVSXFpLXZBcFI2VjF5cGxGUVEyNXFVRUhoTzdHaFFmNmFFZXNtU0gtNU1LaThZR2ZIUEpRV0t2S0lvTHlPUkc?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Jazz Pharmaceuticals (JAZZ) After A 93% One Year Rally?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgJBVV95cUxQUTl5NE1hcXB3djJKRmZSelM0YUhKbXNyXy1zbWpwTlRjQlBINWNZOVVCbUJDWjFjMnFLS2FneFp4UE52MTNXR0ZwaktlaEFDaXNzM09CcDd6LXBvSWxiZ2tvQVJudlo5aVdSSVUydUFlcUFRa3h5QnY5eS1iejNRN0I4UzJIOHlGMGlLX21MczhDYjkyNDB1NzJjQzNrRTl2aFpOYTlLMDR4b1JjWlhXelZmUVlWRS1zQnpCLTBsczZyb2FDYmk1aHRuSE1jMjFrV3h3eExfalRvb0RwREh5djNRTC01WHF3T2V3ZUVwVnZqQk14emFjTEdyZ3FKRFZCWVVpM2dn?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Who Owns Jazz Pharmaceuticals? Top Shareholders and Recent Insider Trades", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQVElHQXlXOGRHTkdHNU1pdXpGNjJXLXFjVjYybXAwbGU2eXBtb1pxMHppRkpYUWV6WnhHRTNIa2tiUTNVTUJNR09WMFQ4eG5nZFptRVhVcDZBcnBMbDF0Y1FwYmR4aGhBWXI0S2hrVjNRcklIcWVjcWdhaXJSWFJ0QUlWNUxlSVo5WVZUbDZFNG13M2h0VUFKQmZCd1FYX2s?oc=5", "source_name": "TIKR.com", "published_at": "2026-01-02T08:00:00+00:00", "published_display": "02 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Improved Revenues Required Before Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 25% Jump Looks Justified", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso\u2122 (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwJBVV95cUxPdkpJZkE3TUNxVzBrd0xEUFVuUnJ3YTVjUHQ0cUVwUGpNN2ZuX2hTVU1UWFZ3TUNJRl9ScUc3ZDZieVB4UFpXNGVsbXBCRjM3eFdEWnI2Tzd3UEQ0OTFPU0ZCZGc5VTJTMGV6aEgyM2h1bm1qbExKb3d1Z3BDZ3FVWW1JaV9ZNlZqMkRCR2JpbnJiaVNlb1pGTFJqRzg4OU1vVVF1amZpM1Q4TGk1ZFlYVzdmZWx5Wnk0V3hFb2h5b3pVRWllN2c5MC03N254UWZOSDZVQ3NUZmhCS2UwYjdVXzJaaml6Q0s4alZ0U0ZObGVNT084TjRWNWdQMGhIMjJua3MyM2wyT2lYRk9Qb1BmVk5qRU40aHJCekRnUjRFQUlDblFnbmhZ?oc=5", "source_name": "PR Newswire", "published_at": "2025-11-11T08:00:00+00:00", "published_display": "11 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 106, "total_relevant": 60, "sentiment_summary": {"positive": 18, "negative": 3, "neutral": 39, "score": 58, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 14.3, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 12.51, "count": 25}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 18, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 247.53, "latest_week": "2026-07-17", "one_week_move": 1.5, "four_week_move": 10.2, "twelve_week_move": 26.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.634419, "market_dynamics_buy_signal": false, "relative_strength": 29.569615, "fair_value_gap": 80.3, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 55.1075, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.5% over one week, +10.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "Stock Titan", "count": 7}, {"label": "Quartr", "count": 7}, {"label": "simplywall.st", "count": 7}, {"label": "PR Newswire", "count": 6}, {"label": "Simply Wall Street", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 25}, {"label": "Analyst action", "count": 6}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+1.5% over one week, +10.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Jazz Pharmaceuticals stock hits all-time high at 250.85 USD"}], "updated_at": "2026-07-21T20:32:12.720383+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}